Liaison sars cov 2 igg serology test

For screening purposes, serum samples were tested for SARS-CoV-2 specific antibodies directed against the viral nucleocapsid (IgA/IgM/IgG) using Elecsys^® Anti-SARS-CoV-2 Ig assay (Roche) on the cobas e411 system (Roche). Additionally, serum samples were tested for SARS-CoV-2 specific antibodies against the S1 and S2 subunits of the viral Spike protein using LIAISON^® SARS-CoV-2 IgG serology test (DiaSorin).
To evaluate serostatus for “common cold” coronaviruses (HCoV) and to further confirm SARS-CoV-2 serostatus, serum antibodies (IgG) against the viral nucleocapsid of HCoV strains 229E, NL63, OC43, HKU1 and SARS-CoV-2 anti - S1 subunit, anti - receptor binding domain as well as anti - nucleocapsid were measured by using the recomLine SARS-CoV-2 IgG^® assay (Mikrogen).
Antibody screening was performed IVD conform according to the manufacturer’s instructions.
Since patient recruiting was performed in a low prevalence setting, (<5%), we used an orthogonal testing algorithm. Therefore, samples were considered as SARS-CoV-2 positive if all three tests were positive, negative in three tests was considered as SARS-CoV-2 negative. Participants with discordant results were excluded from later analysis. Unexposed controls were required to report no known SARS-CoV-2 exposure and to be negative in the SARS-CoV-2 PCR test and in the three antibody tests.

SARS-CoV-2-specific antibodies (IgA/IgM/IgG) against the viral nucleocapsid protein were detected in sample serum using the Elecsys® Anti-SARS-CoV-2 Ig assay (Roche) on the cobas e411 system (Roche). Positive results were confirmed in the same serum sample with the LIAISON® SARS-CoV-2 IgG serology test (DiaSorin). This alternative assay allows for quantification of SARS-CoV-2 antibodies (IgG) against the S1 and S2 subunits of the spike protein. Assays were performed IVD conform according to the manufacturer’s recommendations including thresholds for positivity (see Supplementary Methods). Following the guidelines of the CDC for a low prevalence setting (< 5%) [12 ], an orthogonal testing algorithm was used; therefore, samples were only considered seropositive if positive results were obtained with both assays. Antibody testing was performed identically with both tests at all follow-up appointments for each participating family member.